Acrivastine, CNS depressants
Do not undertake tasks requiring mental alertness
Alcohol, CNS depressants
It is recommended not to take alcohol due to additive depressive effect on the central nervous system
Alfentanyl [1], CNS depressants ---> SmPC of [1] of eMC
CNS depressants may enhance or prolong the respiratory depressant effects of alfentanil.
Alimemazine [1], CNS depressants ---> SmPC of [1] of eMC
The sedative effects of phenothiazines may be intensified (additively) by other sedatives
Alizapride, CNS depressants
Increased CNS depressant effect
Alprazolam [1], CNS depressants ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur in case of concomitant use of alprazolam with other CNS depressants
Amantadine, CNS depressants
Additive CNS toxicity
Amisulpride [1], CNS depressants ---> SmPC of [1] of eMC
Caution is advised when coadministering amisulpride with CNS depressants
Amitriptyline, CNS depressants
Enhancement of the sedative effects. The concomitant use should be done with caution
Amitriptylinoxide, CNS depressants
The combination may potentiate the effect of amitriptylinoxide
Anaesthetics, CNS depressants
The co-administration of anesthetic agents with CNS depressants may have synergistic effects
Antihistamines, CNS depressants
Antihistamines may have additive effects with other CNS depressants
Apraclonidine [1], CNS depressants ---> SmPC of [1] of eMC
The possibility of an additive or potentiating effect with CNS depressants should be considered.
Aripiprazole [1], CNS depressants ---> SmPC of [1] of EMA
Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with other CNS medicinal products with overlapping adverse reactions such as sedation
Asenapine [1], CNS depressants ---> SmPC of [1] of EMA
Caution should be used when asenapine is taken in combination with other centrally acting medicinal products.
Azelastine, CNS depressants
Azelastine may enhance sedation effects of other medicinal products as tranquilizers, hypnotics and alcohol
Baclofen [1], CNS depressants ---> SmPC of [1] of eMC
The concomitant administration of baclofen and other medications that have a suppressing effect on functions of the central nervous system can enhance the action of baclofen
Barbiturates, CNS depressants
The co-administration may mutually enhance the CNS depressant effects
Benperidol [1], CNS depressants ---> SmPC of [1] of eMC
Benperidol can increase the CNS depression produced by other CNS-depressant drugs
Benzodiazepines, CNS depressants
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Brimonidine [1], CNS depressants ---> SmPC of [1] of EMA
The possibility of an additive or potentiating effect with CNS depressants should be considered.
Brinzolamide/brimonidine [1], CNS depressants ---> SmPC of [1] of EMA
Caution is advised due to the possibility of an additive or potentiating effect of brinzolamide/brimonidine with CNS depressants
Bromazepam, CNS depressants
Enhancement of the depressor effect on the central nervous system
Bromperidol, CNS depressants
The co-administration may cause increased tiredness, drowsiness and respiratory disorders
Brotizolam, CNS depressants
The co-administration of brotizolam with other central nervous system depressants may enhance the central nervous depressant effect
Buprenorphine [1], CNS depressants ---> SmPC of [1] of EMA
This combination increases central nervous system depression.
Buprenorphine/naloxone [1], CNS depressants ---> SmPC of [1] of EMA
The combination increases the central nervous system depression
Buspirone, CNS depressants
The sedative effect of buspirone can be enhanced when co-administered with CNS depressants
Butyrophenones, CNS depressants
Additive effect
Cannabidiol [1], CNS depressants ---> SmPC of [1] of EMA
Other CNS depressants, including alcohol, can potentiate the somnolence and sedation effect.
Cariprazine [1], CNS depressants ---> SmPC of [1] of EMA
Given the primary central nervous system effects of cariprazine, Reagila should be used with caution in combination with other centrally acting medicinal products and alcohol.
Carisoprodol, CNS depressants
The co-administration may enhance the depressive effect on the central nervous system.
Celiprolol, CNS depressants
Additive effect
Cenobamate [1], CNS depressants ---> SmPC of [1] of EMA
Concomitant use of cenobamate with other CNS depressants, including alcohol, barbiturates, and benzodiazepines may increase the risk of neurological adverse reactions.
Cetirizine, CNS depressants
Increased CNS depressant effect
Chlomethiazole, CNS depressants
Possible mutual potentiation of effects
Chlordiazepoxide [1], CNS depressants ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur if chlordiazepoxide is combined with other CNS-depressant drugs.
Chlorphenamine, CNS depressants
Increased CNS depressant effect
Chlorpromazine [1], CNS depressants ---> SmPC of [1] of eMC
The co-administration may increase the CNS depressant effect
Chlorprothixene, CNS depressants
The co-administration of chlorprothixene with CNS depressants may cause strong sedation or respiratory depression
Cinnarizine [1], CNS depressants ---> SmPC of [1] of eMC
Concurrent use of cinnarizine and CNS depressants may potentiate the sedative effects
Clobazam [1], CNS depressants ---> SmPC of [1] of eMC
Especially when clobazam is administered at higher doses, an enhancement of the central depressive effect may occur in cases of combination with other central depressive drugs
Clomipramine [1], CNS depressants ---> SmPC of [1] of eMC
Tricyclic antidepressants may potentiate the effects of other central depressant substances
Clonazepam [1], CNS depressants ---> SmPC of [1] of eMC
Enhanced effects on sedation, respiration and haemodynamics may occur when clonazepam is co-administered with any centrally acting depressants
Clonidine, CNS depressants
Clonidine may potentiate the effects of CNS depressants
Cloperastine, CNS depressants
Increased CNS depressant effect
Clozapine [1], CNS depressants ---> SmPC of [1] of eMC
Clozapine may enhance the central effects of CNS depressants
CNS depressants [1], flupentixol ---> SmPC of [1] of eMC
In common with other antipsychotics, flupentixol enhances the response to other CNS depressants.
CNS depressants [1], lofepramine ---> SmPC of [1] of eMC
Effects of lofepramine may be potentiated when administered with CNS depressant substances
CNS depressants [1], pholcodine ---> SmPC of [1] of eMC
Pholcodine may enhance the sedative effect of central nervous system depressants
CNS depressants [1], procarbazine ---> SmPC of [1] of eMC
Procarbazine may enhance the effect of other central nervous system depressants
CNS depressants, CNS depressants
The concomitant use of other CNS depressants, may produce additive depressant effects
CNS depressants, codeine
The co-administration may cause additive depression of CNS
CNS depressants, cyclizine
Cyclizine may have additive effects with other central nervous system depressants
CNS depressants, cyproheptadine [2] ---> SmPC of [2] of eMC
Antihistamines may have additive effects with other CNS depressants
CNS depressants, dantrolene
The co-administration of dantrolene and CNS depressants should be avoided due to the adverse reactions of dantrolene may be enhanced (specially the CNS depressant effect and muscle weakness)
CNS depressants, dapoxetine [2] ---> SmPC of [2] of eMC
Caution is advised if the concomitant administration of dapoxetine and CNS active medicinal products is required
CNS depressants, desflurane
The co-administration of anesthetic agents with CNS depressants may have synergistic effects
CNS depressants, dexchlorpheniramine
The combination of dexchlorpheniramine with other CNS depressants may enhance the CNS depressant effect
CNS depressants, dextromethorphan
The co-administration of dextromethorphan with CNS depressants can result in mutual potentiation of effects
CNS depressants, dextromethorphan/quinidine [2] ---> SmPC of [2] of EMA
Caution should be used when dextromethorphan/quinidine is taken in combination with other centrally acting medicinal products that might increase the risk of adverse reactions such as somnolence and dizziness.
CNS depressants, diamorphine
The co-administration of diamorphine with other CNS depressants may enhance the adverse effects of diamorphine, especially respiratory depression
CNS depressants, diazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur
CNS depressants, dihydrocodeine [2] ---> SmPC of [2] of eMC
Opiates potentiate the effects of CNS depressants
CNS depressants, dimenhydrinate
Dimenhydrinate may increase the effects of other CNS depressors and enhance the sedative effects
CNS depressants, dimethindene
The sedative effect of CNS depressant drugs may be enhanced
CNS depressants, diphenhydramine [2] ---> SmPC of [2] of eMC
Diphenhydramine has additive effects with other CNS depressants resulting in increased antimuscarinic and sedative effects.
CNS depressants, dipotassium clorazepate
The combination of CNS depressors may mutually potentiate the depressor effect on the CNS
CNS depressants, doxylamine
Antihistaminic agents have additive effects with other CNS depressants
CNS depressants, esketamine [2] ---> SmPC of [2] of EMA
Concomitant use of Spravato with CNS depressants (e.g., benzodiazepines, opioids, alcohol) may increase sedation, which therefore should be closely monitored.
CNS depressants, ethosuximide
Enhancement of the sedative effects. The co-administration should be avoided
CNS depressants, ethyl loflazepate
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
CNS depressants, fenfluramine [2] ---> SmPC of [2] of EMA
Pharmacodynamic interactions with other central nervous system depressants increase the risk of aggravated central nervous system depression.
CNS depressants, fentanyl [2] ---> SmPC of [2] of EMA
The concomitant use of fentanyl with other central nervous system depressants may produce additive depressant effects.
CNS depressants, flunitrazepam
The co-administration may cause a mutual potentiation of effects
CNS depressants, fluphenazine [2] ---> SmPC of [2] of eMC
The co-administration may cause a mutual potentiation of effects
CNS depressants, flurazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
CNS depressants, fluspirilene
Mutual enhancement of effects
CNS depressants, guanfacin [2] ---> SmPC of [2] of EMA
Caution should be used when Intuniv is administered concomitantly with CNS depressant medicinal products due to the potential for additive pharmacodynamic effects such as sedation and somnolence.
CNS depressants, haloperidol [2] ---> SmPC of [2] of eMC
In common with all neuroleptics, haloperidol can increase the central nervous system depression produced by other CNS-depressant drugs.
CNS depressants, homatropine
If homatropine is systemic absorbed, the CNS depressant may cause seizures, coma and extrapyramidal symptoms
CNS depressants, hydrocodone
The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects
CNS depressants, hydromorphone [2] ---> SmPC of [2] of eMC
Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression
CNS depressants, hydroxyzine [2] ---> SmPC of [2] of eMC
Patients should be warned that hydroxyzine may enhance their response to other CNS depressants
CNS depressants, imipramine [2] ---> SmPC of [2] of eMC
Tricyclic antidepressants may potentiate the CNS depressant effects of central depressant drugs
CNS depressants, isocarboxazid
Concurrent administration of isocarboxazid with other central nervous system depressants may lead to potentiation of their effects.
CNS depressants, isoflurane [2] ---> SmPC of [2] of eMC
Opioids, benzodiazepines and other sedative agents are associated with respiratory depression, and caution should be exercised when concomitantly administered with isoflurane.
CNS depressants, ketamine [2] ---> SmPC of [2] of eMC
The use of ketamine with other central nervous system (CNS) depressants can potentiate CNS depression and/or increase risk of developing respiratory depression.
CNS depressants, ketotifen
Ketotifen may potentiate the effects of CNS depressants
CNS depressants, levomepromazine
The co-administration of levomepromazine with other central nervous depressants will cause a greater depressant effect on central nervous system
CNS depressants, levomethadone
Enhancement of effects and adverse effects, particularly respiratory depression
CNS depressants, lidocaine
Concomitant use of lidocaine and CNS depressants may cause additive depressor effect. Special caution is recommended
CNS depressants, lisuride
The sedative effects of lisuride may be enhanced by CNS depressant drugs
CNS depressants, loprazolam [2] ---> SmPC of [2] of eMC
Combination with CNS depressants causes enhancement of the central depressive effects of loprazolam.
CNS depressants, lorazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if lorazepam is combined with other CNS depressants
CNS depressants, lormetazepam
The benzodiazepines, including lormetazepam produce additive CNS depressant effects when co-administered with other medications which themselves produce CNS depression
CNS depressants, loxapine [2] ---> SmPC of [2] of EMA
Loxapine may cause severe respiratory depression if combined with other CNS-depressants
CNS depressants, lurasidone [2] ---> SmPC of [2] of EMA
Given the primary central nervous system effects of lurasidone, lurasidone should be used with caution in combination with other centrally acting medicinal products and alcohol.
CNS depressants, maprotiline
Maprotiline may enhance the effects of CNS depressant
CNS depressants, medazepam
The co-administration of medazepam with other central nervous system depressants may enhance the central nervous depressant effect.
CNS depressants, melperone
An enhancement of the central depressive effect may occur in cases of combination of melperone with other central depressive drugs
CNS depressants, meprobamate
Meprobamate may increase the effects of concurrently administered central nervous system depressants.
CNS depressants, meptazinol
Concomitant use of meptazinol and SNC depressants may mutually enhance the fatigue
CNS depressants, mequitazine
Central nervous system depressants may enhance the sedative effects of mequitazine
CNS depressants, methadone
Enhancement of respiration inhibitor and sedative effect of methadone
CNS depressants, methocarbamol
Methocarbamol may potentiate the effects of other central nervous system depressants and stimulants
CNS depressants, methyldopa
Enhancement of CNS depressor effect
CNS depressants, metoclopramide
The co-administration may mutually enhance the sedative effects of the CNS. The combination requires caution
CNS depressants, mianserin
Mianserin may enhance the central depressive effect
CNS depressants, midazolam [2] ---> SmPC of [2] of EMA
The co-administration of midazolam with other sedative/hypnotic agents and CNS depressants, including alcohol, is likely to result in enhanced sedation and respiratory depression.
CNS depressants, mitotane [2] ---> SmPC of [2] of EMA
Mitotane can cause central nervous system undesirable effects at high concentrations. This should be borne in mind when co-prescribing medicinal products with central nervous system depressant action.
CNS depressants, morphine [2] ---> SmPC of [2] of eMC
Morphine sulphate potentiates the effects of other central nervous depressants
CNS depressants, nabilone
Nabilone should be administered with caution to patients who are taking other CNS depressants
CNS depressants, nalbuphine
Other central nervous system depressant drugs may increase the risk of respiratory depression, which can be life-threatening in the case of an overdose
CNS depressants, narcotine
Noscapine with other CNS depressant drugs may increase the sedation and somnolence of the CNS depressants
CNS depressants, neuroleptics
Potentiation may occur if antipsychotic drugs are combined with CNS depressants
CNS depressants, nicomorphine
The co-administration may mutually enhance the sedative and respiratory depressor effect
CNS depressants, nitrazepam
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
CNS depressants, nitrous oxide
Additive effect on the CNS. It should be taken into account the pronounced sedative risk and depression of the protective reflexes
CNS depressants, nortriptyline
The co-administration of nortriptyline and CNS depressants may increase the depressive effects on the CNS
CNS depressants, noscapine
Noscapine with other CNS depressant drugs may increase the sedation and somnolence of the CNS depressants
CNS depressants, olanzapine [2] ---> SmPC of [2] of EMA
Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.
CNS depressants, opipramol
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
CNS depressants, oxatomide
The co-administration may increase the CNS depressant effect
CNS depressants, oxazepam
Enhancement of other CNS depressant drugs
CNS depressants, oxomemazine
Enhancement of CNS depressant effect
CNS depressants, oxycodone [2] ---> SmPC of [2] of eMC
Central nervous system depressants can enhance the adverse reactions of oxycodone, in particular respiratory depression.
CNS depressants, paliperidone [2] ---> SmPC of [2] of EMA
Given the primary CNS effects of paliperidone, it should be used with caution in combination with other centrally acting medicines.
CNS depressants, pentazocine [2] ---> SmPC of [2] of eMC
Agents with sedative action can enhance the central depressant effects of pentazocine
CNS depressants, pentoxyverine
The use of CNS-depressors may enhance the sedative and respiratory depressive effects
CNS depressants, perampanel [2] ---> SmPC of [2] of EMA
Increased levels of anger, confusion, and depression when perampanel is used in combination with other central nervous system (CNS) depressants.
CNS depressants, perazine
The co-administration of perazine with CNS depressants may cause strong sedation or respiratory depression
CNS depressants, periciazine
Mutual enhancement of effects
CNS depressants, perphenazine
Risk of sedation and/or toxicity when perphenazine is administered with CNS depressants
CNS depressants, pethidine [2] ---> SmPC of [2] of eMC
The central depressant effects of pethidine may be potentiated by the concurrent use of other CNS depressants; respiratory depression and profound sedation or coma may occur.
CNS depressants, phenelzine [2] ---> SmPC of [2] of eMC
Phenelzine may potentiate the action of CNS depressants
CNS depressants, phenobarbital [2] ---> SmPC of [2] of eMC
Concurrent administration of phenobarbital with other CNS depressants may lead to an additive CNS depressant effects
CNS depressants, phenothiazines
Phenothiazine may enhance the effect of other CNS depressants
CNS depressants, phenytoin
Phenytoin with CNS depressants may enhance the central nervous system depression
CNS depressants, pimozide [2] ---> SmPC of [2] of eMC
As with other neuroleptics, pimozide may increase the central nervous system depression produced by other CNS depressant drugs
CNS depressants, pipamperone
Potentiation of the depressor effect on the CNS
CNS depressants, pipotiazine [2] ---> SmPC of [2] of eMC
The CNS depressant actions of neuroleptic agents may be intensified (additively) by other sedatives. Respiratory depression may occur.
CNS depressants, piritramide
The co-administration may enhance the adverse effects of piritramide, particularly respiratory depression
CNS depressants, pizotifen
The co-administration may enhance the depressive effect on the central nervous system
CNS depressants, prazepam
Concomitant use of prazepam and other CNS depressant drugs can mutually enhance the effects
CNS depressants, pregabalin [2] ---> SmPC of [2] of EMA
In the postmarketing experience, there are reports of respiratory failure and coma in patients taking pregabalin and other CNS depressant medicinal products.
CNS depressants, primidone
The CNS depressant effect of primidone is additive to those of other CNS depressants
CNS depressants, prochlorperazine
CNS depressants should be used with caution
CNS depressants, promazine
The concomitant administration of promazine with central nervous system depressants (including alcohol and anaesthetics) may result in accentuation of their effects
CNS depressants, promethazine
The co-administration of promethazine and other central nervous depressants can mutually enhance the effects and adverse reactions (particularly sedation and hypotension)
CNS depressants, propofol
The co-administration may enhance the sedative effect. The parenteral use of a CNS depressant may decrease strongly the respiratory and cardiovascular function
CNS depressants, propranolol
The co-administration may enhance the antihypertensive effect
CNS depressants, prothipendyl
The combination of prothipendyl and CNS depressants may mutually enhance the effects
CNS depressants, quazepam
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
CNS depressants, quetiapine [2] ---> SmPC of [2] of eMC
Given the primary central nervous system effects, quetiapine should be used with caution in combination with other centrally acting medicinal products and alcohol.
CNS depressants, remifentanil [2] ---> SmPC of [2] of eMC
If doses of concomitantly administered CNS depressant medicinal products are not reduced patients may experience an increased incidence of adverse effects associated with these agents.
CNS depressants, reserpine
The co-administration may enhance the CNS depressant effect of reserpine
CNS depressants, risperidone [2] ---> SmPC of [2] of eMC
Risperidone should be used with caution in combination with CNS depressants due to the increased risk of sedation
CNS depressants, rotigotine [2] ---> SmPC of [2] of EMA
Because of possible additive effects, caution should be advised when patients are taking sedating medicinal products or other CNS (central nervous system) depressants or alcohol in combination with rotigotine.
CNS depressants, rupatadine [2] ---> SmPC of [2] of eMC
As with other antihistamines, interactions with CNS depressants cannot be excluded.
CNS depressants, selegiline [2] ---> SmPC of [2] of eMC
Concomitant use selegiline and central suppressant drugs and should be avoided.
CNS depressants, sodium oxybate [2] ---> SmPC of [2] of EMA
Sodium oxybate should not be used in combination with sedative hypnotics or other CNS depressants.
CNS depressants, sufentanil [2] ---> SmPC of [2] of EMA
The concomitant use of CNS depressants including barbiturates, benzodiazepines, neuroleptics or other opioids, halogen gases or other non-selective CNS depressants (e.g. alcohol) may enhance respiratory depression.
CNS depressants, sulpiride
Sulpiride enhances the sedative effect of CNS depressant
CNS depressants, tapentadol [2] ---> SmPC of [2] of eMC
The co-administration may enhance the sedative effect of tapentadol
CNS depressants, temazepam
Enhancement of the central depressive effect may occur if temazepam is combined with other CNS depressants
CNS depressants, tetrabenazine
The co-administration of tetrabenazine with CNS depressant drugs may have an additive sedative effect
CNS depressants, tetracyclic antidepressant
The antidepressant may potentiate the effects of other central depressant substances
CNS depressants, tetrazepam
The co-administration may mutually enhance the CNS depressant effects
CNS depressants, thiethylperazine
The co-administration may potentiate the CNS depressant effect
CNS depressants, thiopental
The CNS depressant can enhance the respiratory depressor effect of thiopental
CNS depressants, thioridazine
Phenothiazine may enhance the effect of other CNS depressants
CNS depressants, thioxanthenes
Additive effect
CNS depressants, tiapride
Enhancement of CNS depressant effect
CNS depressants, tilidine
Enhancement of CNS depressant effect, particularly respiratory depression
CNS depressants, topiramate [2] ---> SmPC of [2] of eMC
It is recommended that topiramate not be used concomitantly with other CNS depressant medicinal products.
CNS depressants, tramadol [2] ---> SmPC of [2] of eMC
Concomitant administration of tramadol with other centrally acting drugs may potentiate CNS depressant effects.
CNS depressants, tranylcypromine
The effect of CNS depressants can be enhanced by co-administration of tranylcypromine
CNS depressants, trazodone
The co-administration may enhance the CNS depressant effect
CNS depressants, triazolam
Benzodiazepins have an additive effect, when are combined with other CNS depressants. Triazolam should be used with caution when it is combined with CNS depressants
CNS depressants, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC
Tricyclic antidepressants may also potentiate the CNS depressant effects of central depressant drugs
CNS depressants, trifluoperazine [2] ---> SmPC of [2] of eMC
Potentiation may occur if antipsychotic drugs are combined with CNS depressants
CNS depressants, trihexyphenidyl
The co-administration may enhance the CNS depressant effect
CNS depressants, trimipramine [2] ---> SmPC of [2] of eMC
The co-administration of trimipramine with other CNS depressants may increase the CNS depressant effect.
CNS depressants, venlafaxine [2] ---> SmPC of [2] of eMC
Caution is advised when venlafaxine is taken in combination with other CNS-active substances
CNS depressants, zaleplon [2] ---> SmPC of [2] of EMA
The co-administration may potentiate the central sedation
CNS depressants, ziprasidone
The possibility of an additive or potentiating effect with CNS depressants should be considered.
CNS depressants, zolpidem [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur in case of concomitant use of zolpidem with other central nervous system depressants
CNS depressants, zopiclone [2] ---> SmPC of [2] of eMC
The combination with CNS depressants an enhancement of the central depressive effect may occur.
CNS depressants, zotepine
The co-administration may cause a mutual potentiation of effects
CNS depressants, zuclopenthixol [2] ---> SmPC of [2] of eMC
Zuclopenthixol enhances the effects of other CNS depressants.